Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.
When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
Our Culture:
At Boundless, you’ll experience what it means to be out in front of the wave.
Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers.
Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless.
We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success.
At Boundless, we’re all in. We are unbound by convention, bound to save lives.
Career Inquiries
careers@boundlessbio.com
General Information Inquiries
info@boundlessbio.com
When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
Our Culture:
At Boundless, you’ll experience what it means to be out in front of the wave.
Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers.
Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless.
We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success.
At Boundless, we’re all in. We are unbound by convention, bound to save lives.
Career Inquiries
careers@boundlessbio.com
General Information Inquiries
info@boundlessbio.com
Location: United States, California, La Jolla
Employees: 51-200
Total raised: $251.4M
Founded date: 2018
Investors 4
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | PFM Health... | pfmhealths... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | RA Capital... | racap.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.05.2023 | Series C | $100M | Logos Capi... |
| 24.05.2021 | Series B | $105M | - |
| 19.09.2019 | Series A | $46.4M | - |
Mentions in press and media 18
| Date | Title | Description |
| 11.09.2024 | Revolutionizing Cancer Diagnostics: The Promise of Liquid Biopsy and ecDNA Detection | In the realm of cancer diagnostics, innovation is the lifeblood. Two recent collaborations highlight a seismic shift in how we approach cancer detection and treatment. SOPHiA GENETICS, a leader in data-driven medicine, is at the forefront o... |
| 05.09.2024 | SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 | The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland, Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENE... |
| 28.03.2024 | Boundless Bio raises $100M from IPO | - |
| 16.05.2023 | Boundless Bio completes a $100M funding round to support the advancement of their preclinical pipeline of candidates | - |
| 16.05.2023 | Boundless Bio Raises $100M in Series C Financing | Boundless Bio, a San Diego, CA-based clinical stage precision oncology company, raised $100M in Series C funding. The round was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation f... |
| 24.05.2021 | Boundless Bio Raises $105 Million Series B Financing | Boundless Bio ... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Subscriber-only digital content every business day, plus full access to SDBJ.com archives Book of Lists... |
| 28.04.2021 | Boundless Bio Picks Up $105M | San Diego-based Boundless Bio, a company developing therapeutics for treating cancer, has raised $105M in its Series B funding, the company said this morning. According to the company, the funding was led by Nextech invest and RA Capital Ma... |
| 28.04.2021 | Boundless Bio has raised a $105M Series B to advance multiple therapeutic programs into the clinic as well as its companion diagnostic | - |
| 28.04.2021 | Boundless Bio : Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) | Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B finan... |
| 28.04.2021 | Boundless Bio Raises $105M Series B | SAN DIEGO, Boundless Bio announced the closing of an oversubscribed $105 Million Series B financing co-led by RA Capital and Nextech. >> Click here for more funding data on Boundless Bio >> To export Boundless Bio funding da... |
Show more